Colin C. Pritchard

University of Washington — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

30h-index9.2kcitations119works3.82yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Genomics and Diagnostics(25), Ovarian cancer diagnosis and treatment(21), Prostate Cancer Treatment and Research(20), Cancer Immunotherapy and Biomarkers(18), PARP inhibition in cancer therapy(17)

Publications119 total

Remote delivery of cancer genetic testing in veterans with metastatic prostate cancer: A Million Veteran Program pilot study
Cancer·2026Open Access
3D pathology-guided microdissection
2025Open Access
CHIMERA-DDR: A Machine Learning Framework for Classifying Heterogeneous Mismatch-Repair and Homologous-Recombination Deficiency Patterns in Prostate Cancer
2025Open Access
Molecular consequences of acute versus chronic CDK12 loss in prostate carcinoma nominates distinct therapeutic strategies
2025· 1 citedOpen Access
2457P CDK12 as a prostate cancer predisposition gene
Annals of Oncology·2025
Does paired genetic testing improve targeted therapy choices and screening recommendations for patients with upper gastrointestinal cancers and their families? A prospective cohort of 42 patients
BMJ Open·2025Open Access
Association of Prior PARP Inhibitor Exposure with Clinical Outcomes after 177Lu-PSMA-617 in Men with Castration-resistant Prostate Cancer and Mutations in DNA Homologous Recombination Repair Genes
European Urology Oncology·2025· 5 citedOpen Access
Molecular consequences of acute versus chronic CDK12 loss in prostate carcinoma nominates distinct therapeutic strategies
2024· 3 citedOpen Access
Molecular consequences of acute versus chronic CDK12 loss in prostate carcinoma nominates distinct therapeutic strategies
2024· 1 citedOpen Access
ESMO Recommendations on clinical reporting of genomic test results for solid cancers
Annals of Oncology·2024· 34 citedOpen Access
PLATIPARP: A phase 2 study of induction docetaxel and carboplatin followed by maintenance rucaparib in treatment of patients with mCRPC with homologous recombination DNA repair deficiency.
Journal of Clinical Oncology·2024
Nivolumab and ipilimumab for metastatic prostate cancer with an immunogenic signature: The NEPTUNES multi-centre two-cohort, biomarker-selected phase 2 trial.
Journal of Clinical Oncology·2024· 7 cited
Association of prior poly(ADP-ribose) polymerase (PARP) inhibitor therapy with response to 177Lu-PSMA-617 (LuPSMA) in men with DNA damage repair (DDR) mutations.
Journal of Clinical Oncology·2024
Real-world effectiveness of PARP inhibitors (PARPi) in metastatic castration-resistant prostate cancer (mCRPC) by genomic homologous recombination repair (HRR) alterations and homologous recombination deficiency signature (HRDsig).
Journal of Clinical Oncology·2024· 2 cited
Digital innovation in the surgical pathway: building a digital pre-operative triage and risk assessment tool using a population health platform
BJA Open·2023Open Access
Final results of a pilot study of docetaxel and carboplatin for treatment of patients with mCRPC containing biallelic inactivation of genes in the homologous recombination DNA repair pathway.
Journal of Clinical Oncology·2023· 1 cited
Supp. Table S2 from Genetic Mechanisms of Immune Evasion in Colorectal Cancer
2023Open Access
Supp. Figures and Legends from Genetic Mechanisms of Immune Evasion in Colorectal Cancer
2023Open Access
Supp. Tables S1, S3-S15, S20, and S23 from Genetic Mechanisms of Immune Evasion in Colorectal Cancer
2023Open Access
Supplementary Tables 1-3, Figures 1-2 and Methods from Blood Cell Origin of Circulating MicroRNAs: A Cautionary Note for Cancer Biomarker Studies
2023Open Access
page 1 of 6Next →

Frequent Co-authors

Tom Walsh(14), Mary‐Claire King(10), Peter S. Nelson(10), Stephen J. Salipante(8), Jonathan F. Tait(6), Ming K. Lee(6), Elizabeth M. Swisher(6), Christina Smith(5), Barbara M. Norquist(4), Silvia Casadei(4), Brian H. Shirts(4), Robin L. Bennett(4), Süleyman Gülsüner(4), Heather H. Cheng(4), Bruce Montgomery(4), Jane E. Churpek(3), Sioḃán Keel(3), Karen M. Koehler(3), David Wu(3), Joaquı́n Mateo(3)